Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial

Geoerger, Birgit; Kang, Hyoung Jin; Yalon-Oren, Michal; Marshall, Lynley V.; Vezina, Catherine; Pappo, Alberto; Laetsch, Theodore W.; Petrilli, Antonio S.; Ebinger, Martin; Toporski, Jacek; Glade-Bender, Julia; Nicholls, Wayne; Fox, Elizabeth; DuBois, Steven G.; Macy, Margaret E.; Cohn, Susan L.; Pathiraja, Kumudu; Diede, Scott J.; Ebbinghaus, Scot; Pinto, Navin

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial

Author:

Geoerger, Birgit; Kang, Hyoung Jin; Yalon-Oren, Michal; Marshall, Lynley V.; Vezina, Catherine; Pappo, Alberto; Laetsch, Theodore W.; Petrilli, Antonio S.; Ebinger, Martin; Toporski, Jacek; Glade-Bender, Julia; Nicholls, Wayne; Fox, Elizabeth; DuBois, Steven G.; Macy, Margaret E.; Cohn, Susan L.; Pathiraja, Kumudu; Diede, Scott J.; Ebbinghaus, Scot; Pinto, Navin

Tübinger Autor(en):

Ebinger, Martin

Published in:

Lancet Oncology (2020), Bd. 21, H. 1, S. 121-133

Verlagsangabe:

Elsevier Science Inc

Language:

English

Full text:

http://dx.doi.org/10.1016/S1470-2045(19)30671-0

ISSN:

1474-5488